Cilostazol, um inibidor da fosfodiesterase III: perspectivas futuras na aterosclerose

Rosa, Marcelo Pereira da; Baroni, Gislaine Verginia; Portal, Vera Lúcia

doi:10.1590/s0066-782x2006001800035

Cited by 8 publications

(7 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-platelet agents have been proposed to be effective in preventing cardiovascular events [ 15 ]. Specifically, sarpogrelate [ 11 ], cilostazol [ 16 ], and clopidogrel [ 17 ] have beneficial effects in the prevention of atherosclerosis in a rabbit model. In our study, treatment with sarpogrelate alone resulted in no reduction in arterial wall plaque formation at a dose of 10 mg/kg, and a marginal and insignificant reduction was observed at 50 mg/kg ( Fig 1A and 1B ).…”

Section: Discussionmentioning

confidence: 99%

Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice

Park

Kwak

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

Pravastatin is a lipid-lowering agent that attenuates atherosclerosis. However, the multifactorial pathogenesis of atherosclerosis requires other drugs with different anti-atherogenic mechanisms. We chose sarpogrelate as an anti-platelet agent and a novel component of a complex drug with pravastatin due to its high potential but little information on its beneficial effects on atherosclerosis. Low-density lipoprotein receptor-knockout mice were fed a high-fat, high-cholesterol diet and treated with pravastatin alone, sarpogrelate alone, or a combination of both drugs. Although sarpogrelate alone did not significantly reduce atherosclerotic plaque areas, co-treatment with pravastatin significantly decreased aortic lesions compared to those of the pravastatin alone treated group. The combined therapy was markedly more effective than that of the single therapies in terms of foam cell formation, smooth muscle cell proliferation, and inflammatory cytokine levels. These results suggest that pravastatin and sarpogrelate combined therapy may provide a new therapeutic strategy for treating atherosclerosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice

Park

Kwak

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Previous studies reported that the rate of drug discontinuation was approximately 15% 73,78) . Cilostazol should be avoided in patients with congestive heart failure of any severity because of increased mortality risk 81,82) .…”

Section: Phosphodiesterase Inhibitorsmentioning

confidence: 99%

Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease

Ueno

Kodali

Tello‐Montoliu

et al. 2011

JAT

View full text Add to dashboard Cite

“…An example is Cilostazol (CLZ), a phosphodiesterase III (FDE3) inhibitor. The drug acts by decreasing calcium intracellularly by increasing cAMP levels [15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Effect of Cilostazol-Loaded PCL/PEG Nanocapsules on Abdominal Aortic Tunics and Lipid Profile of Wistar Rats

Pilatti

Rodrigues

Nascimento

et al. 2020

Braz. arch. biol. technol.

View full text Add to dashboard Cite

Cilostazol (CLZ) is a phosphodiesterase III inhibitor with antiplatelet and vasodilator properties. It has been recently verified that CLZ plays a significant role in the arteries by inhibiting the proliferation and growth of muscle cells, increasing the release of nitric oxide by the endothelium and promoting angiogenesis. Considering these promising effects, the use of nanocapsules may be an interesting strategy to optimize its pharmacokinetics and pharmacodynamics at the vascular level for preventing atherosclerosis. The aim of this study was to evaluate the effect of cilostazol-loaded nanocapsules in the abdominal aortic tunics and on the lipid profile of Wistar rats in order to investigate its potential role in the prevention of atherosclerosis. Thirty-two animals were divided into four groups of eight animals, with 30-day treatment. Group 1 received nanoencapsulated CLZ; Group 2, control nanocapsules with no drug; Group 3, propylene glycol and water; and Group 4, a solution of CLZ in propylene glycol and water. After 30 days, there was no statistically significant difference between the groups regarding the cellularity and thickness of the arterial tunics of the abdominal aorta. However, the group that received nanoencapsulated CLZ (Group 1) had an improvement in HDL-c and triglyceride values compared to unloaded nanocapsules (Group 2).

show abstract

Cilostazol, um inibidor da fosfodiesterase III: perspectivas futuras na aterosclerose

Cited by 8 publications

References 77 publications

Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice

Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice

Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease

Effect of Cilostazol-Loaded PCL/PEG Nanocapsules on Abdominal Aortic Tunics and Lipid Profile of Wistar Rats

Contact Info

Product

Resources

About